Can personalized antibiotics outsmart resistant bacteria in liver transplants?

NCT ID NCT07759453

First seen Aug 12, 2026 · Last updated Aug 13, 2026 · Updated 1 time

Summary

This trial tests whether giving liver transplant patients antibiotics tailored to the specific resistant bacteria they carry (CPE) can prevent infections better than standard antibiotics. It involves adults colonized with CPE who are undergoing a liver transplant. Researchers will compare the two approaches to see which reduces early infections and how they affect gut bacteria.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Targeted antibiotic prophylaxis using ceftazidime-avibactam or meropenem-vaborbactam, chosen based on the specific resistant bacteria each patient carries
What this could lead to
If effective, this approach could reduce dangerous infections after liver transplant in patients carrying resistant bacteria, potentially improving survival and recovery.
What could go wrong
The trial is relatively small and early, and results may not apply to all patients. There are also risks of antibiotic side effects and disruption of gut bacteria.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARBAPENEM-RESISTANT ENTEROBACTERALES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Azienda Ospedaliera Universitaria Citta Della Salute E Della Scienza Di Torino

    Torino, TO, 10126, Italy

  • Azienda Ospedaliero Universitaria Pisana

    Pisa, PI, 56126, Italy

  • Irccs Azienda Ospedaliero-Universitaria Di Bologna

    Bologna, BO, 40138, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.